The use of thalidomide in androgen-independent prostate cancer

被引：13

作者：

Cox, Michael C. ^{[1
]}

Dahut, William L. ^{[1
]}

Figg, William D. ^{[1
]}

机构：

[1] NCI, Mol Pharmacol Sect, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2006年 / 24卷 / 03期

基金：

美国国家卫生研究院;

关键词：

angiogenesis; prostate cancer; hormones; thalidomide; oncology;

D O I：

10.1016/j.urolonc.2005.11.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

More than 200,000 men will be diagnosed with prostate cancer during the year 2006. Approximately 20% to 30% of these cases may develop advanced disease, for which there currently is no cure. Although therapy for this disease has improved significantly over the past few years, with docetaxel treatment showing improved survival times in metastatic disease, there remains the need for improved treatment options. Dr. Folkman put forth the idea of angiogenesis in 1971, and, since that time, researchers have been trying to determine the best possible way to inhibit blood vessel formation. This review summarizes the use of thalidomide in androgen-independent prostate cancer and the results of trials conducted at the National Cancer Institute. Published by Elsevier Inc.

引用

页码：246 / 249

页数：4

共 28 条

[1] Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide [J].

Ando, L ;

Price, DK ;

Dahut, WL ;

Cox, MC ;

Reed, E ;

Figg, WD .

CANCER BIOLOGY & THERAPY, 2002, 1 (06) :669-673

[2]

Ando Y, 2002, CLIN CANCER RES, V8, P1964

[3] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J].

Bauer, KS ;

Dixon, SC ;

Figg, WD .

BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) :1827-1834

[4]

Bok RA, 2001, CANCER RES, V61, P2533

[5]

Bostwick D G, 1998, Semin Urol Oncol, V16, P118

[6] A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].

CRAWFORD, ED ;

EISENBERGER, MA ;

MCLEOD, DG ;

SPAULDING, JT ;

BENSON, R ;

DORR, FA ;

BLUMENSTEIN, BA ;

DAVIS, MA ;

GOODMAN, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424

[7] Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer [J].

Dahut, WL ;

Gulley, JL ;

Arlen, PM ;

Liu, Y ;

Fedenko, KM ;

Steinberg, SM ;

Wright, JJ ;

Parnes, H ;

Chen, CC ;

Jones, E ;

Parker, CE ;

Linehan, WM ;

Figg, WD .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2532-2539

[8] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[9] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer [J].

Drake, MJ ;

Robson, W ;

Mehta, P ;

Schofield, I ;

Neal, DE ;

Leung, HY .

BRITISH JOURNAL OF CANCER, 2003, 88 (06) :822-827

[10]

Figg WD, 2001, CLIN CANCER RES, V7, P1888

← 1 2 3 →